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Abstract: The bone marrow-derived stem/progenitor cells were demonstrated to play an important role in a regeneration of
damaged tissue. Based on these observations we asked whether the stroke-related stress triggers mobilization of stem/progenitor
cells from the bone marrow into the peripheral blood, which subsequently could contribute to regeneration of damaged organs.
To address this issue, the peripheral blood samples were harvested from patients with ischemic stroke during the first 24 hrs
as well as after the 48 (2nd day) and 144 hrs (6th day) since the manifestation of symptoms. In these patients we evaluated the
percentage of hematopoietic stem/progenitor-enriched CD34+ cells by employing flow cytometry and the number of hemato-
poietic progenitor cells for the granulocyto-monocytic (CFU-GM) and erythroid (BFU-E)-lineages circulating in peripheral
blood. We concluded that stress related to ischemic stroke triggers the mobilization of hematopoietic stem/progenitor cells
from the bone marrow into peripheral blood. These circulating stem/progenitor cells may play an important role in the process
of regeneration of the ischemic tissue. (www.cm-uj.krakow.pl/FHC)
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Introduction
Ischemic stroke leads to the degeneration of brain tissue
supplied by the occluded vessel. This produces a lesion
cavity and results in neurological deficits. The disease is
the leading cause of death and disability worldwide [16].
Organ and tissue repair is a constant phenomenon which
occurs during normal life [12]. This process may be
driven by stem cells that reside in bone marrow and in
other tissues [15, 17]. Bone marrow (BM)- or mobilized
peripheral blood (mPB)-derived stem cell implants have
been reported to regenerate damaged organs, including
brain [2, 14, 20, 25]. Bone marrow-derived stem cells
have been shown to be able to differentiate in in vitro
cultures into neurons, cardiac myocytes, smooth
muscle- and endothelial cells [4, 5, 11, 19]. Similarly,
they were reported to regenerate ischemic brain tissue in
vivo. Human bone marrow mesenchymal stem cells
engrafted into the cortex surrounding the area of infarc-
tion significantly improved the functional performance
in limb placement test in rats [25]. In the same study,
histological examination revealed that transplanted
human mesenchymal stem cells expressed markers for
astrocytes, oligodenroglia and neurons. Subcutaneous
administration of granulocyte colony-stimulating factor
(G-CSF) into rats resulted in diminished cerebral infarc-
tion and improved motor performance after right middle
cerebral artery ligation [20]. These observations awoke
many hopes for the development of new stem cell based
therapeutic strategies to ameliorate neurological deficits
in patients after stroke.
However, whether the bone marrow-derived pro-
genitor/stem cells play a role in the regeneration of
damaged tissue is not clear at this point. Generally, the
beneficial effect of these cells in regeneration of dam-
aged organs could be explained by (1) trans-dedifferen-
tiation/plasticity of hematopoietic stem cells [1], (2)
paracrine secretion of angiopoietic factors from BM-
derived stem/progenitor cells which leads to an im-
proved vascularization of the damaged organ, or (3)
what we have recently postulated - by the presence of a
heterogeneous population of tissue-committed stem
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cells (e.g., for myocardium and endothelium) in the BM
[15, 17]. 
The circulating pool of stem cells can be increased
by pharmacological mobilization from the BM. The
progenitor/stem-enriched CD34+ cells could be mobi-
lized into peripheral blood by administration of growth
factors (e.g. granulocyte colony-stimulating factor G-
CSF), or chemotherapeutics (e.g. cyclophosphamide),
or a combination of both [22]. Mobilized peripheral
blood hematopoietic stem cells are increasingly used for
allogeneic hematopoietic transplantations. The ex-
pression of the CD34 surface antigen characterizes a
heterogeneous population of cells including hemato-
poietic stem/progenitor cells (HSPC), endothelial pro-
genitor cells (EPC), mature endothelial cells and, as we
recently reported, tissue-committed stem cells (TCSC)
[6]. Although the true role of the CD34 molecule con-
tinues to be debated, CD34+ HSPC have been function-
ally defined as capable of generating progenitor-derived
clones in vitro and, by their potential, of reconstituting
the lymphomyelopoietic system in myelocompromised
hosts [13, 21, 24]. CD34+ cells were also reported to be
mobilized after heart infarct [23]. However, there is no
data available on mobilization of CD34+ cells after
ischemic stroke. 
Thus, the aim of this study was to evaluate the
stroke-related stress mobilization of progenitor/stem-
enriched CD34+ cells from the bone marrow into periph-
eral blood. We evaluated the total number of circulating
CD34+ cells by flow cytometry and the number of cir-
culating hematopoietic clonogeneic progenitors: CFU-
GM (colony forming unit of granulocytes and
macrophages) and BFU-E (burst forming unit of ery-
throcytes) by employing ex vivo cell culture assays in
patients with ischemic stroke. The evaluation of these
cells in peripheral blood was performed during the first
24 hrs of manifestation of symptoms as well as on the
2nd and 6th day afterwards. 
Materials and methods
Patients. Peripheral blood samples (4 mL) were harvested from 25
patients with ischemic stroke. The samples were collected during the
first 24 hrs of manifestation of symptoms as well as on the 2nd and
6th day of the stroke. In each case the stroke had been precisely
documented clinically by computer tomography (CT). Patients were
recruited from the inpatient population of the Clinic of Neurology,
Pomeranian Medical University, Szczecin, Poland. Peripheral blood
samples were also harvested from 12 healthy donors, which were
treated as a control group. An approval from the Local Ethical
Committee was obtained. Moreover, the donors gave written in-
formed consent in each case. The patients’ characteristics is sum-
marized in Table 1.
Clonogeneic assays. Light-density mononuclear cells (MNC) were
obtained after centrifugation over Gradisol L (Polfa, Poland) as
described previously [9]. Cells isolated from peripheral blood were
subsequently depleted of adherent cells (A-MNC), plated in methyl-
cellulose cultures and stimulated to form granulocyte-monocytic
(CFU-GM) and erythroid (BFU-E) colonies. CFU-GM colonies
were stimulated with GM-CSF (granulocyte-macrophage colony
stimulating factor) + IL3 (interleukin-3). BFU-E colonies were
stimulated with specific human recombinant growth factors: EPO
(erythropoietin) + KL (kit ligand) + IL3, as described elsewhere [18].
The ex vivo colonies were subsequently identified and counted using
an inverted microscope, as described previously [18]. Cultures were
performed in quadruplicate.
Flow cytometry. At the same time the percentage of CD34+ cells in
peripheral blood was evaluated by employing immunostaining with
anti-CD34 monoclonal antibodies (Becton-Dickinson, CA, USA)
and flow cytometry (FACScan, Becton-Dickinson, CA, USA), as
described previously [8] (Fig. 1).
Automatic cell count. The absolute number of leukocytes and
lymphocytes in peripheral blood were determined at the same time
with an automatic cell counter (Cell-Dyn 3500, Abbott, USA).
Statistical analysis. The arithmetic means and standard deviations
were calculated on an IBM computer using Statistica. The cells were
cultured in quadruplicate at each point. The data were analyzed using
Kruskal-Wallis test. The values showing significant differences in
the Kruskal-Wallis test were next analyzed using the Mann-Whitney
U-test. Statistical significance was defined as P<0.05. 
Results
We found that the number of CD34+ cells was signifi-
cantly higher (P<0.05) in peripheral blood of patients
after ischemic stroke as compared to the healthy control
group (Fig. 2). Furthermore, we noticed differences in
the number of myeloid (CFU-GM) and erythroid (BFU-
E) progenitors circulating in the peripheral blood of
patients with ischemic stroke as compared to healthy
controls (Fig. 3). The number of circulating clonogeneic
CFU-GM, was significantly higher after 24 hrs, on day
2 and 6 after stroke (P<0.05). In the case of BFU-E, the
number of these cells in peripheral blood was also slight-
ly higher, however, this increase was not statistically
significant.
The absolute number of leukocytes and lymphocytes
in peripheral blood of patients with ischemic stroke
during the first 24 hours of manifestation of symptoms,
on the 2nd day and on the 6th day afterwards, and of
healthy control group is shown in Table 2. 
Control Stroke
Age [yrs] 58±26 67±29
Men/Women 7/3 16/10
Hypertension [%] 0 79
Hypercholesterolemia [%] 0 "
Diabetes [%] 0 21
Smoking [%] 0 25
Table 1. Characteristics of patients with ischemic stroke and healthy
control group
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Of note, no significant correlation was found in any
patient between the number of circulating hematopoietic
progenitor cells (CFU-GM and BFU-E) and circulating
CD34+ cells on one hand and evaluated parameters such
as patient age, sex, presence of diabetes mellitus, hyper-
tension and smoking habits on the other. 
Fig. 1. Representative flow-cyto-
metry measurements of the number
of CD34+ cells in peripheral blood of
patient with ischemic stroke. CD34+
cells were detected by employing
phycoerythrin-conjugated anti-
CD34 monoclonal antibodies. Iso-
type-matched antibodies were used
as a control. 
Fig. 2. Number of circulating CD34+ cells in patients with ischemic
stroke 24 hours (24 hrs), 48 hrs (2nd day) and 144 hrs (6th day) after
manifestation of symptoms and in healthy control group (control).
The number of CD34+ cells is expressed per µL of peripheral blood.
Fig. 3. Number of circulating early hematopoietic stem/progenitor
cells (clonogenic CFU-GM and BFU-E) in patients with ischemic
stroke 24 hours (24 hrs), 48 hrs (2nd day) and 144 hrs (6th day) after
manifestation of symptoms and in healthy control group (control).
The number of clonogeneic progenitors are expressed per µL of
peripheral blood.
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Discussion
Human hematopoietic stem and progenitor cells (HSPC)
reside in a complex bone marrow microenvironment
consisting of a diverse population of stromal cells and
extracellular matrix produced by these cells [7]. How-
ever, under physiological conditions relatively small
amounts of primitive stem cells continuously leave BM
and circulate in the peripheral blood in order to keep in
balance the stem cell pool distributed in remote tissue
niches that are located in different organs [3]. The num-
ber of these cells may be increased in peripheral blood
after so-called pharmacological mobilization [22]. The
multiple mechanisms and factors that regulate HSPC
mobilization from bone marrow into peripheral blood
are still not fully understood. We attempted to answer
the question whether stroke-related stress may also trig-
ger mobilization of early stem/progenitor-enriched
CD34+ cells from the bone marrow into the peripheral
blood. The results obtained in our study support this
notion. 
Accordingly, we noticed by employing flow cyto-
metry a higher number of circulating CD34+ cells in
stroke-affected patients as compared to the healthy con-
trols. We also demonstrate here for the first time that the
number of circulating CD34+ cells as well as clonoge-
neic CFU-GM and BFU-E is significantly higher during
the first 6 days in patients affected by stroke. 
In the available literature there are no data published
on the number of circulating CD34+ cells in stroke
patients. We are aware that at this point it is still prema-
ture to speculate on the biological function of these
mobilized early hematopoietic stem/progenitor cells.
First, these cells may accompany mobilization of other
more primitive hematopoietic and non-hematopoietic
stem cells (e.g., endothelial-, neural- or cardiac-stem
cells) that are mobilized into peripheral blood in an
attempt to regenerate damaged tissues (e.g., brain).
Thus, they could serve as an indicator of stroke-related
stress and reflect the general response of an organism to
tissue/organ damage. Second, as we demonstrated in the
past, that hematopoietic CD34+ progenitor cells are a
rich source of several pro-angiopoietic factors [10].
Thus, it is possible that they may home to the damaged
tissues/organs and by secreting angiopoietic factors con-
tribute to neovascularization. These possibilities will be
tested in our further investigations. 
In conclusion, our study has demonstrated for the
first time that CD34+ clonogeneic hematopoietic
stem/progenitor cells are mobilized into peripheral
blood in patients after stroke. Thus, stress related to
stroke may increase the number of early CD34+ HSPC
in peripheral blood. Whether along with these stroke-
mobilized hematopoietic stem/progenitors other tissue-
committed stem cells, e.g. neural TCSC or endothelial
TCSC are also mobilized, will be the subject of our
further investigations. We postulate that these circulat-
ing stem/progenitor cells may play an important role in
regeneration of ischemic brain, however, further studies
are needed to elucidate the mechanisms involved in this
phenomenon. 
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